Psoriasis Treatment - An Engineered Locked Dimer of the Human Chemokine CCL20
The psoriasis market for prescription therapies is projected to reach nearly $8.2 billion in 2020 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. Our CCL20 locked dimer would be benchmarked against topicals (such as clobetasol propionate, a steroidal anti-inflammatory commonly used as the initial treatment for psoriasis patients) injectable systemic therapies (such as anti-TNF monoclonal antibody, TNF inhibitors, and anti-IL-12/23 monoclonal antibody), and new oral therapies (such Otezla and Xeljanz). Anti-TNF agents occasionally have unpredictable side effects including the development of new skin eruptions. They broadly inhibit TNF-alpha, a cytokine involved in many aspects of immune defense against pathogens. Our CCL20 locked dimer acts further downstream, potentially making it more specific than the agents in current use but just as effective.
Please view the complete technology summary and additional publications at "Technology page URL"
美国
